Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06945419 | A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes | PHASE1 | RECRUITING | 216 | — | — | Apr 23, 2025 | Jul 1, 2026 | May 12, 2026 | 5 | United States, Singapore |
| Arm | Type | Description |
|---|---|---|
| Part A: LY4086940 Single Dose (Healthy Participants) | EXPERIMENTAL | Participants will receive a single dose of LY4086940 orally |
| Part A: Placebo Single Dose (Healthy Participants) | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo orally |
| Part A: LY4086940 Multiple Dose (Healthy Participants) | EXPERIMENTAL | Participants will receive LY4086940 orally for 3 days |
| Part A: Placebo Multiple Dose (Healthy Participants) | PLACEBO_COMPARATOR | Participants will receive placebo orally for 3 days |
| Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity) | EXPERIMENTAL | Participants will receive LY4086940 orally for 4 weeks |
| Part B: Placebo Multiple Dose (Participants with Overweight or Obesity) | PLACEBO_COMPARATOR | Participants will receive placebo orally for 4 weeks |
| Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity) | EXPERIMENTAL | Participants will receive LY4086940 orally for 4 weeks |
| Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity | PLACEBO_COMPARATOR | Participants will receive placebo orally for 4 weeks |
| Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity) | EXPERIMENTAL | Participants will receive LY4086940 orally for 4-6 weeks |
| Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity) | PLACEBO_COMPARATOR | Participants will receive placebo orally for 4-6 weeks |
| Part E (Open-Label): LY4086940 Single Dose (Healthy Participants) | EXPERIMENTAL | Participants will receive a single dose of LY4086940 intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| LY4086940 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have no significant body weight change for the 3 months prior to screening Part A and Part E: * Are considered healthy * Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening Part B: * Have a BMI of 27 to 45 kg/m2 at screening Part C: *...